Physician profile
Manuel Astruc
NPI 1700863255
$19,905.73
in general payments reported to CMS, 2019-2025
27 companies · $3,148 in 2025
The $3,148 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $967 · 2021: $1,503 · 2022: $2,272 · 2023: $9,341 · 2024: $2,428 · 2025: $3,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,596 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Consulting Fee: $3,000 · Education: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,596.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Consulting Fee | $3,000.00 |
| Education | $320.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $6,038.01 | 2021-2023 | Brainsway Deep Tms |
| Abbvie INC. | $3,272.78 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $1,619.65 | 2022-2025 | Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,243.80 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,192.04 | 2020-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $964.00 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $770.10 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $736.06 | 2020-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $656.84 | 2022-2025 | Auvelity |
| Alkermes, INC. | $629.58 | 2019-2025 | Aristada, Lybalvi |
| Corium, LLC | $496.52 | 2022-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $442.38 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $399.41 | 2020-2022 | |
| Allergan, INC. | $370.49 | 2020 | |
| Supernus Pharmaceuticals, INC. | $242.09 | 2021-2025 | Qelbree, Qelbree |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $209.77 | 2019-2025 | Rexulti, Abilify Maintena |
| Idorsia Pharmaceuticals US INC | $207.82 | 2023-2024 | Quviviq |
| Shire North American Group INC | $100.13 | 2019 | |
| Novo Nordisk INC | $83.97 | 2022-2023 | |
| Bausch Health US, LLC | $58.54 | 2022-2023 | Wellbutrin, Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $34.39 | 2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $32.61 | 2022 | |
| Almatica Pharma LLC | $31.37 | 2022 | |
| Biogen, INC. | $22.86 | 2025 | Zurzuvae |
| Indivior INC. | $18.19 | 2025 | Sublocade |
| Ironshore Pharmaceuticals INC. | $16.54 | 2023 | Jornay Pm |
| Alfasigma USA, INC. | $15.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Astruc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.